Botulinum Toxin — MCQs

10 questions

Which of the following is the shortest-acting competitive neuromuscular blocking agent?

How does botulinum toxin affect synaptic transmission?

A 40-year-old man presents with sudden onset of unilateral facial paralysis. He is unable to close his eye or raise his eyebrow. What is the most likely diagnosis?

Evidence based therapy of Bell's palsy include(s):

A 40-year-old woman with severe tension headaches presents after failing medical therapy. What is the most appropriate next step in management?

The mechanism of action of botulinum toxin A is best described by:

Botulinum toxin is used in -

Exocytic release of acetylcholine is blocked by

All are true about spasmodic dysphonia EXCEPT:

Q10

All of the following statements are true about Frey's Syndrome except

Botulinum Toxin Indian Medical PG Practice Questions and MCQs

Question 1: Which of the following is the shortest-acting competitive neuromuscular blocking agent?

A. Atracurium
B. Rocuronium
C. Mivacurium (Correct Answer)
D. Cisatracurium

Explanation: ***Mivacurium*** - Mivacurium is characterized by its **rapid onset** and **ultrashort duration** of action, primarily due to its hydrolysis by plasma pseudocholinesterase [3]. - This rapid metabolism makes it highly suitable for procedures requiring **brief neuromuscular blockade** or when rapid recovery is desirable. *Atracurium* - Atracurium has an **intermediate duration** of action and is primarily metabolized by **Hofmann elimination**, a non-enzymatic chemical degradation, and ester hydrolysis [3]. - While it's useful in patients with renal or hepatic dysfunction, its duration is significantly longer than mivacurium [4]. *Rocuronium* - Rocuronium is an **intermediate-acting** neuromuscular blocking agent known for its **rapid onset** of action, making it a common choice for **rapid sequence induction** [1]. - Its duration of action is longer than mivacurium and it is primarily eliminated by the kidneys and liver [2]. *Cisatracurium* - Cisatracurium is an **intermediate-acting** neuromuscular blocker that is an isomer of atracurium [3]. - It also undergoes **Hofmann elimination**, but it is more potent and produces fewer histamine release issues than atracurium, yet its duration is still longer than mivacurium [3].

Question 2: How does botulinum toxin affect synaptic transmission?

A. Prevents ACh release (Correct Answer)
B. Inhibits Ca2+ release
C. Increases K+ influx
D. Blocks Na+ channels

Explanation: ***Prevents ACh release*** - Botulinum toxin acts by **cleaving SNARE proteins** (SNAP-25, synaptobrevin, syntaxin) which are essential for the fusion of acetylcholine (ACh) vesicles with the presynaptic membrane [2]. - By preventing vesicle fusion, it effectively **blocks the release of ACh** into the synaptic cleft, leading to muscle paralysis [1, 2]. *Inhibits Ca2+ release* - While **calcium influx** is crucial for neurotransmitter release, botulinum toxin's primary mechanism is not direct inhibition of calcium release from the sarcoplasmic reticulum or entry into the presynaptic terminal. - Its action is further downstream, targeting the machinery involved in **vesicle fusion** rather than the initial calcium signal. *Increases K+ influx* - An increase in **potassium (K+) influx** would typically cause hyperpolarization or counteract depolarization, which is not the direct action of botulinum toxin. - Botulinum toxin specifically targets the **release mechanism of neurotransmitters**, not the ion channels responsible for maintaining resting membrane potential or repolarization. *Blocks Na+ channels* - Blocking **sodium (Na+) channels** would prevent depolarization and action potential generation, similar to the mechanism of local anesthetics. - Botulinum toxin does not directly interfere with sodium channel function; its effect is focused on the **vesicular release process of acetylcholine**.

Question 3: A 40-year-old man presents with sudden onset of unilateral facial paralysis. He is unable to close his eye or raise his eyebrow. What is the most likely diagnosis?

A. Myasthenia gravis
B. Trigeminal neuralgia
C. Bell's palsy (Correct Answer)
D. Stroke

Explanation: ***Bell's palsy*** - **Bell's palsy** presents as an **idiopathic, sudden-onset, unilateral facial nerve paralysis** affecting both the upper and lower face (inability to close eye or raise eyebrow). - This condition is thought to be due to **inflammation or compression of the facial nerve (CN VII)**, leading to a complete hemifacial weakness or paralysis [2]. *Myasthenia gravis* - **Myasthenia gravis** is an **autoimmune disorder** primarily affecting the **neuromuscular junction**, causing fluctuating muscle weakness that worsens with activity and improves with rest. - While it can affect facial muscles, it typically presents with **ptosis**, **diplopia**, and generalized weakness, not an acute unilateral paralysis of the entire hemiface. *Trigeminal neuralgia* - **Trigeminal neuralgia** is characterized by **brief, severe, electric shock-like pains** in the distribution of the **trigeminal nerve (CN V)**, often triggered by touch or movement. - It does not cause muscle weakness or paralysis, but rather sensory symptoms and pain. *Stroke* - A **stroke** causing facial paralysis typically results in **sparing of the forehead** (the patient can still raise their eyebrow) because the upper facial muscles receive bilateral cortical innervation [1]. - While a stroke can cause sudden unilateral weakness, the inability to raise the eyebrow is a key differentiating feature making Bell's palsy more likely [2].

Question 4: Evidence based therapy of Bell's palsy include(s):

A. Steroid (Correct Answer)
B. Facial nerve massage
C. Acyclovir
D. Facial nerve stimulation

Explanation: ***Steroid*** - **Corticosteroids**, such as prednisone, are the mainstay of treatment for Bell's palsy, particularly when initiated early (within 72 hours of symptom onset) [1]. - They work by reducing **inflammation and swelling** of the facial nerve, which can alleviate compression and promote recovery. *Facial nerve massage* - While supportive therapies like physical therapy can be helpful for **muscle re-education** and preventing contractures, facial nerve massage itself is not an evidence-based therapy for improving nerve function in acute Bell's palsy. - Its efficacy in **nerve regeneration** or speeding recovery has not been scientifically proven. *Acyclovir* - **Antivirals** like acyclovir or valacyclovir are sometimes used in conjunction with steroids if a **herpes simplex virus (HSV) etiology** is suspected, but their standalone use for Bell's palsy is not evidence-based and their benefit in addition to steroids is debated [1]. - The primary evidence points to a viral etiology in some cases, but the direct benefit of antivirals over steroids alone is not consistently robust across studies. *Facial nerve stimulation* - **Electrical stimulation** of the facial nerve is not recommended and may even be harmful in the acute phase of Bell's palsy. - It has not been shown to improve outcomes and can potentially impede natural nerve regeneration or cause **synkinesis** [1].

Question 5: A 40-year-old woman with severe tension headaches presents after failing medical therapy. What is the most appropriate next step in management?

A. Opioid analgesics
B. Nerve decompression surgery
C. Botox injections for chronic tension-type headaches
D. Cognitive behavioral therapy (Correct Answer)

Explanation: ***Cognitive behavioral therapy*** - **CBT** has strong evidence as **primary therapy** for chronic tension-type headaches failing medical management, helping patients develop coping strategies and modify pain-related behaviors. - It can significantly **reduce headache frequency and intensity** in tension-type headaches by addressing psychological triggers, stress management, and muscle tension patterns. *Opioid analgesics* - **Opioid analgesics** are generally **contraindicated** for chronic headache management due to the significant risks of **medication overuse headache (MOH)**, dependence, tolerance, and other side effects [1]. - They provide only temporary relief and can worsen headache prognosis over time, making them an inappropriate long-term strategy, especially after failing other therapies [1]. *Nerve decompression surgery* - **Nerve decompression surgery** (e.g., occipital nerve decompression) is a **highly specialized** and **invasive** procedure for very specific types of refractory headaches, such as occipital neuralgia or certain chronic migraines. - It is typically considered only after **all other conservative and less invasive medical and interventional therapies** have failed, and after thorough diagnostic workup to confirm a surgically amenable nerve entrapment. *Botox injections for chronic tension-type headaches* - **OnabotulinumtoxinA (Botox)** is FDA-approved specifically for **chronic migraine**, not for tension-type headaches, making it inappropriate for this clinical scenario. - Off-label use would not constitute the **"most appropriate next step"** when evidence-based treatments like CBT exist specifically for tension-type headaches.

Question 6: The mechanism of action of botulinum toxin A is best described by:

A. Slowing of myelinated nerve fiber transmission
B. Postsynaptic receptor blockade
C. Acetylcholinesterase inhibition
D. Presynaptic blockade of acetylcholine release (Correct Answer)

Explanation: ***Presynaptic blockade of acetylcholine release*** - **Botulinum toxin A** acts by cleaving specific proteins (**SNARE proteins** like SNAP-25, synaptobrevin, and syntaxin) essential for the fusion of **acetylcholine-containing vesicles** with the presynaptic membrane. - This prevents the release of acetylcholine into the **neuromuscular junction**, leading to muscle paralysis. *Slowing of myelinated nerve fiber transmission* - This describes the action of agents that affect **myelin sheaths** (e.g., demyelinating diseases) or ion channels involved in action potential propagation, not the mechanism of botulinum toxin. - Botulinum toxin specifically targets the **synaptic transmission**, not the speed of nerve conduction itself. *Postsynaptic receptor blockade* - This mechanism is seen with drugs like **curare** or **neuromuscular blockers** (e.g., rocuronium, vecuronium), which compete with acetylcholine for binding to **nicotinic acetylcholine receptors** on the muscle endplate. - Botulinum toxin does not affect the postsynaptic receptors directly; its action is entirely presynaptic. *Acetylcholinesterase inhibition* - **Acetylcholinesterase inhibitors** (e.g., neostigmine, pyridostigmine) prevent the breakdown of acetylcholine in the synaptic cleft, increasing its concentration and prolonging its action. - This mechanism would enhance, rather than block, muscle contraction, which is opposite to the effect of botulinum toxin.

Question 7: Botulinum toxin is used in -

A. Myasthenia gravis
B. Cerebellar ataxia
C. Focal dystonia (Correct Answer)
D. Hypotonia

Explanation: ***Focal dystonia*** - **Botulinum toxin** is a potent neurotoxin that relaxes muscles by blocking the release of **acetylcholine** at the neuromuscular junction. - In **focal dystonia**, specific muscles contract involuntarily, causing abnormal postures or movements; botulinum toxin injections can temporarily paralyze these muscles, reducing symptoms. *Myasthenia gravis* - **Myasthenia gravis** is an **autoimmune disease** characterized by muscle weakness due to antibodies blocking **acetylcholine receptors** at the neuromuscular junction. - Injecting **botulinum toxin** would further weaken the already compromised muscles, exacerbating the condition, and is therefore contraindicated. *Cerebellar ataxia* - **Cerebellar ataxia** results from damage to the **cerebellum**, leading to problems with coordination, balance, and fine motor control. - **Botulinum toxin** acts on the neuromuscular junction and would not address the underlying neurological deficit in the cerebellum. *Hypotonia* - **Hypotonia** refers to decreased muscle tone, often caused by problems in the brain, spinal cord, nerves, or muscles. - Using **botulinum toxin**, which causes muscle paralysis, would worsen **hypotonia** by further reducing muscle tone and strength.

Question 8: Exocytic release of acetylcholine is blocked by

A. Hemicholinium (inhibits choline reuptake)
B. Alphabungarotoxin (blocks ACh at receptors)
C. Vesamicol (interferes with ACh loading)
D. Botulinum toxin (blocks release of ACh) (Correct Answer)

Explanation: ***Botulinum toxin (blocks release of ACh)*** - **Botulinum toxin** acts by cleaving SNARE proteins (SNAP-25, synaptobrevin, syntaxin) which are essential for the fusion of synaptic vesicles with the presynaptic membrane, thereby **blocking exocytic release of acetylcholine**. - This blockage prevents the release of neurotransmitter from the nerve terminal, leading to muscle paralysis or reduced glandular secretions. *Hemicholinium (inhibits choline reuptake)* - **Hemicholinium** inhibits the high-affinity reuptake of **choline** into the presynaptic neuron, which is a crucial step in the synthesis of acetylcholine. - While it depletes acetylcholine stores over time, it does not directly block the immediate exocytic release of already synthesized acetylcholine. *Alphabungarotoxin (blocks ACh at receptors)* - **Alpha-bungarotoxin** is a potent antagonist that binds irreversibly and competitively to **nicotinic acetylcholine receptors (nAChR)** on the postsynaptic membrane. - Its action is postsynaptic, meaning it blocks the effect of acetylcholine once released, rather than preventing its release from the presynaptic terminal. *Vesamicol (interferes with ACh loading)* - **Vesamicol** inhibits the **vesicular acetylcholine transporter (VAChT)**, which is responsible for loading newly synthesized acetylcholine into synaptic vesicles. - By preventing the packaging of acetylcholine into vesicles, vesamicol reduces the amount of neurotransmitter available for release, but it does not directly block the exocytosis mechanism itself.

Question 9: All are true about spasmodic dysphonia EXCEPT:

A. Responds well to botulinum toxin
B. Adductor type is more common
C. Usually bilateral involvement
D. More common in children (Correct Answer)

Explanation: ***More common in children*** - Spasmodic dysphonia is primarily a disorder affecting **adults**, with onset typically occurring between the ages of 30 and 50 years. - It is **rarely seen in children**, and when voice disorders occur in children, they are usually due to other causes like vocal nodules or muscle tension dysphonia. *Responds well to botulinum toxin* - **Botulinum toxin (Botox) injections** into the laryngeal muscles are considered the **gold standard treatment** for spasmodic dysphonia. - It effectively paralyzes the spasmodic muscles, providing **significant symptomatic relief** for several months. *Adductor type is more common* - The **adductor type**, characterized by a strained, choked, or squeezed voice quality, accounts for approximately **85-90% of all spasmodic dysphonia cases**. - This is due to involuntary spasms that cause the vocal cords to slam together too tightly. *Usually bilateral involvement* - Spasmodic dysphonia primarily involves the **laryngeal intrinsic muscles**, and the spasms are often **bilateral**, affecting muscles on both sides of the larynx. - While one side might be more affected, the underlying neurological dysfunction typically manifests with **bilateral muscle activation abnormalities**.

Question 10: All of the following statements are true about Frey's Syndrome except

A. Less chances with enucleation than parotidectomy
B. Gustatory sweating
C. Aberrant misdirection of parasympathetic fibers of auriculotemporal nerve
D. Sympathetic nerve involvement is the primary cause (Correct Answer)

Explanation: ***Sympathetic nerve involvement is the primary cause*** - **This is FALSE (Correct answer for EXCEPT question)** - Frey's syndrome is **NOT** caused by sympathetic nerve involvement - The primary cause is **aberrant regeneration of severed PARASYMPATHETIC fibers** of the auriculotemporal nerve - These parasympathetic fibers mistakenly re-innervate sweat glands (which are sympathetically innervated) instead of the parotid gland - This misdirection causes gustatory sweating during meals *Less chances with enucleation than parotidectomy* - **TRUE** - Enucleation is a less extensive procedure compared to complete parotidectomy - Less tissue removal means less nerve disruption and lower risk of auriculotemporal nerve damage - The risk of Frey's syndrome is directly proportional to the extent of parotid tissue removal *Gustatory sweating* - **TRUE** - This is the hallmark symptom of Frey's syndrome - Characterized by sweating on the skin over the parotid region in response to salivary stimuli (smelling, seeing, or eating food) - Results from misdirected parasympathetic fibers stimulating sweat glands instead of salivary tissue *Aberrant misdirection of parasympathetic fibers of auriculotemporal nerve* - **TRUE** - This is the correct pathophysiological mechanism underlying Frey's syndrome - Following injury to the auriculotemporal nerve during parotid surgery, regenerating parasympathetic secretomotor fibers become misdirected - These fibers intended for the parotid gland instead innervate sweat glands in the overlying skin

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free